Local increase in polymorphonuclear leukocyte elastase is associated with tumor invasiveness in non-small cell lung cancer.

The production of tumor cell proteases is implicated in tumor cell invasion and metastasis. To determine whether lung cancer cells can produce polymorphonuclear leukocyte elastase (PMN-E), we measured the concentration of immunoreactive (ir)-PMN-E in the conditioned medium of seven lines of non-small cell lung cancer cells, EBC-1, LC-1sq, LK-2, A-549, PC-3, RERF-LC-MS, and RERF-LC-OK, and three normal lung epithelial cell lines, CCD-8Lu, WI-1003, and LL-24, by using a recently developed enzyme immunoassay (EIA). We measured the concentration of ir-PMN-E in extracts of 40 non-small cell lung cancers, and evaluated its association with the clinicopathologic findings in these patients. The ir-PMN-E level in the culture medium increased with time in six of the seven lines of lung cancer cells; the exception was PC-3. No detectable ir-PMN-E was secreted into the culture medium of the three lines of normal lung epithelial cells. The ir-PMN-E was detected in tissue extracts from 34 to 40 specimens at concentrations ranging from 0.11 to 15.5 micrograms/100 mg of protein. When 40 specimens of lung cancer were categorized by clinical stage of disease, the ir-PMN-E concentration was significantly higher in stage IIIB vs stages I, II, or IIIA. Similarly, the ir-PMN-E concentration was significantly higher in stage IIIA than in stage I. Evaluation of correlations between the ir-PMN-E concentration and patient characteristics showed that the ir-PMN-E level was significantly higher in T3 and T4 tumors than in T1 or T2 tumors. Analysis of prognostic factors in a group of 101 patients with non-small cell lung cancer demonstrated that those with high ir-PMN-E had a significantly shorter overall survival vs those with a low ir-PMN-E at the cutoff point of 3.5 micrograms/100 mg of protein. Multivariate analysis showed that ir-PMN-E was a significant porgnostic factor for early death (hazard ratio, 4.04; 95% confidence interval, 1.65 to 9.95) (p = 0.005), suggesting it was an independent marker for prognosis. Results suggest that the local production of PMN-E may be involved in the tumor invasion associated with a poor prognosis in patients with non-small cell lung cancer.

[1]  I. Banga,et al.  Elastase and Elastase-Inhibitor , 1949, Nature.

[2]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[3]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[4]  A. Janoff,et al.  Mediators of inflammation in leukocyte lysosomes. IX. Elastinolytic activity in granules of human polymorphonuclear leukocytes. , 1968 .

[5]  L. Sandberg,et al.  Structural features of tropoelastin related to the sites of cross-links in aortic elastin. , 1971, Biochemistry.

[6]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[7]  Y. Shimosato,et al.  Neuronal differentiation of oat cell carcinoma in vitro by dibutyryl cyclic adenosine 3′,5′-monophosphate , 1975 .

[8]  J. Travis,et al.  Human leukocyte granule elastase: rapid isolation and characterization. , 1976, Biochemistry.

[9]  W. Hornebeck,et al.  Elastogenesis and elastinolytic activity in human breast cancer. , 1977, Biomedicine / [publiee pour l'A.A.I.C.I.G.].

[10]  A. Kang,et al.  Degradation of type IV (basement membrane) collagen by a proteinase isolated from human polymorphonuclear leukocyte granules. , 1980, The Journal of biological chemistry.

[11]  J. McDonald,et al.  Degradation of fibronectin by human leukocyte elastase. Release of biologically active fragments. , 1980, The Journal of biological chemistry.

[12]  Y. Shimosato,et al.  Histological Typing of Lung Tumours 1 , 1981 .

[13]  Z. Werb,et al.  Mouse macrophage elastase. Purification and characterization as a metalloproteinase. , 1981, The Biochemical journal.

[14]  S. Neumann,et al.  Enzyme-linked immunoassay for human granulocyte elastase in complex with alpha 1-proteinase inhibitor. , 1984, Advances in experimental medicine and biology.

[15]  S. Horiuchi,et al.  Plasminogen activator as a functional marker for estrogen dependence in human breast cancer cells. , 1986, Japanese journal of cancer research : Gann.

[16]  D. Rifkin,et al.  Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade , 1986, Cell.

[17]  Y. Kawakami,et al.  Simultaneous flow cytometric detection of nuclear DNA and tumor-associated antigens in lung cancers. , 1988, Analytical and quantitative cytology and histology.

[18]  W. Owen,et al.  An elastase-dependent pathway of plasminogen activation. , 1989, Biochemistry.

[19]  W. McGuire,et al.  Cathepsin D and prognosis in breast cancer. , 1990, The New England journal of medicine.

[20]  S. Ménard,et al.  Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors , 1991, International journal of cancer.

[21]  K. Sugimachi,et al.  Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. , 1991, Cancer research.

[22]  D. Ferrigno,et al.  Prognostic value of the tissue polypeptide antigen in lung cancer. , 1992, Chest.

[23]  H. Dosaka-akita,et al.  Prognostic significance of the expression of ras oncogene product in non‐small cell lung cancer , 1992, Cancer.

[24]  C. Angeletti,et al.  The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node‐negative non‐small cell lung cancer , 1992, Cancer.

[25]  M. Stearns,et al.  Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue. , 1993, Cancer research.

[26]  S. Gruber,et al.  Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Varani,et al.  Human skin in organ culture. Elaboration of proteolytic enzymes in the presence and absence of exogenous growth factors. , 1995, The American journal of pathology.